title: Rifampicin for Idiopathic Granulomatous Lobular Mastitis: A Promising Alternative for Treatment.
abstract: Idiopathic granulomatous lobular mastitis (IGLM) is a chronic, non-caseating, inflammatory breast disease of obscure aetiology characterized by multiple masses, abscesses and sinus formation. There is no standard treatment to date, but surgical procedures and systemic corticosteroids are effective in its treatment despite high recurrence rates.
  
  
  
  This prospective study including 30 patients with IGLM between November 2012 and May 2016 aimed to investigate the possibility of administration of Rifampicin (300 mg twice daily for a period of 6-9 months) as an alternative therapy for both surgery and corticosteroids in patients with IGLM. All patients were diagnosed by core needle biopsy.
  
  
  
  All patients were of reproductive age and had a history of breast feeding, which is the most important predisposing factor for IGLM. The mean age was 31.6 ± 5.8 years (range 23-42 years). Eighteen patients (60%) were treated by Rifampicin for 6 months, whereas 12 patients (40%) were treated for 9 months. Twelve months after the beginning of therapy, all patients showed complete clinical and ultrasonographic responses. No serious side effects were reported to stop the treatment course. The median follow-up after finishing the course of treatment was 15.5 months (average 3-35 months) with no episodes of disease relapse.
  
  
  
  Rifampicin is effective in the treatment of patients with IGLM with complete clinical and ultrasonographic response after 6-9 months and could be used as a solo medical therapy alternative to both surgery and corticosteroids.
authors.affiliation: Surgical Oncology Department, Faculty of Medicine, Oncology Center-Mansoura University (OCMU), Mansoura, Egypt. dr_omarfarouk@yahoo.com.
authors.forename: Omar
authors.initials: O
authors.lastname: Farouk
authors.affiliation: Surgical Oncology Department, Faculty of Medicine, Oncology Center-Mansoura University (OCMU), Mansoura, Egypt.
authors.forename: Mohamed
authors.initials: M
authors.lastname: Abdelkhalek
authors.affiliation: Surgical Oncology Department, Faculty of Medicine, Oncology Center-Mansoura University (OCMU), Mansoura, Egypt.
authors.forename: Ahmed
authors.initials: A
authors.lastname: Abdallah
authors.affiliation: Clinical Pharmacology Department, Faculty of Medicine, Mansoura University, Mansoura, Egypt.
authors.forename: Ahmed
authors.initials: A
authors.lastname: Shata
authors.affiliation: Surgical Oncology Department, Faculty of Medicine, Oncology Center-Mansoura University (OCMU), Mansoura, Egypt.
authors.forename: Ahmed
authors.initials: A
authors.lastname: Senbel
authors.affiliation: Surgical Oncology Department, Faculty of Medicine, Oncology Center-Mansoura University (OCMU), Mansoura, Egypt.
authors.forename: Essam
authors.initials: E
authors.lastname: Attia
authors.affiliation: Surgical Oncology Department, Faculty of Medicine, Oncology Center-Mansoura University (OCMU), Mansoura, Egypt.
authors.forename: Mohamed Abd
authors.initials: MA
authors.lastname: Elghaffar
authors.affiliation: Surgical Oncology Department, Faculty of Medicine, Oncology Center-Mansoura University (OCMU), Mansoura, Egypt.
authors.forename: Mahmoud
authors.initials: M
authors.lastname: Mesbah
authors.affiliation: Diagnostic Radiology Department, Faculty of Medicine, Mansoura University, Mansoura, Egypt.
authors.forename: Nermine
authors.initials: N
authors.lastname: Soliman
authors.affiliation: Pathology Department, Faculty of Medicine, Mansoura University, Mansoura, Egypt.
authors.forename: Maha
authors.initials: M
authors.lastname: Amin
authors.affiliation: Pathology Department, Faculty of Medicine, Mansoura University, Mansoura, Egypt.
authors.forename: Dina
authors.initials: D
authors.lastname: El-Tantawy
mesh_terms: D000328:Adult; D000900:Anti-Bacterial Agents / Q000627:therapeutic use*; D005260:Female; D005500:Follow-Up Studies; D058890:Granulomatous Mastitis / Q000188:drug therapy*; D006801:Humans; D011446:Prospective Studies; D012293:Rifampin / Q000627:therapeutic use*; D055815:Young Adult
chemical_list: D000900:Anti-Bacterial Agents; D012293:Rifampin